



Abbreviations: IV = intravenous.


Note: Dashed line represents where the median average concentration would be expected for a 300-mg fixed IV dose. The overall average doses in the 50-mg and 200-mg cohorts during induction were 100 mg and 250 mg, respectively.

Figure 1: **Population PK model-estimated average serum concentrations of mirikizumab**




Note: Concentration points are at the median of the PK model-estimated average concentration in the placebo, 50-mg, 200-mg, and 600-mg groups from left to right.

Figure 2: Rates at Week 12 for induction endpoints of interest relative to average concentration of mirikizumab in each dose group




Note: Areas labeled Tertile 1, 2, and 3 are the tertiles of the model-estimated average concentrations for all patients who received LY3074828 (mirikizumab). The overall average doses in the 50-mg and 200-mg groups during induction were 100 mg and 250 mg, respectively.

Figure 3: Model-estimated average concentration of mirikizumab during induction in patients based on clinical response (upper panel) or clinical remission (lower panel) status



Note: Areas labeled Tertile 1, 2, and 3 are the tertiles of the observed Week 12 concentrations for all patients who received LY3074828 (mirikizumab). The overall average doses in the 50-mg and 200-mg groups during induction were 100 mg and 250 mg, respectively.

Figure 4: Observed Week 12 concentration of mirikizumab during induction in patients based on clinical response (upper panel) or clinical remission (lower panel) status



Abbreviations: PI = projection interval; Bio Naive = biologic-naive; Bio Experienced = biologic-experienced.

Note: Projection intervals are based on simulation of 500 replicated trials with an N = 500 each for biologic-naive and biologic-experienced patients. Vertical dashed lines represent the median expected Week 12 concentrations for fixed IV doses administered Q4W.

Figure 5: Model-simulated change in modified Mayo score at Week 12 versus Week 12 concentration of mirikizumab